The investigator proposes an 18 month, feasibility pilot study, randomizing obese and
diabetic individuals with pure uric acid nephrolithiasis (UAN) or mixed calcium oxalate (CO)
UAN to either phentermine/topiramate or a pragmatic control group who will remain on their
standard medication regimen (citrate salts, allopurinol, diet, etc.).
Phase:
Phase 3
Details
Lead Sponsor:
University of Florida
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)